

Figure S1. RBD and S protein ELISA reactivity with plasma from healthy donors.

The reactivity of healthy human plasma against SARS-CoV-2 RBD and S protein was assessed by ELISA assay.

Name	Sequence
316-549(RBD)	SNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPKLNDLCFTNVYAD SFVIRGDEVRQIAPGQTGKIADYNKLPDDFTGCVIAWNSNNLDSKGNNYNYLYRLFRKSNLKPFERDISTEIQAGSTP C NGVEGFNCYFP LQSYGQOPTNGVGYQPYRVVVLSELLHAPATVCGPKKSTNLVKNKCVNFNGLTGTGVLTESNKKFL PFQQFGRDIADTTDAVRDPQTLEILDITPCSGGGVSITPGNTNSQAVLYQDVNCTEVPAIHADQLPTWRVYSTGSN VFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQNSPRRARSVASQSIAYTMSLGAENSVAYSNSNIAPTNFTISVTTEI LPVSMTKTSVDCTMYICGDESTCSNLLQYGSFCTQLNALTGIAVEQDKNTQEVAQVKQIYKTPPIKDFGGFNFSQILPD PSKPSKRKFIEDLLFNKVTLADAGFIKQYGDCLGRIAARDLICAQKFNGLTVLPL
S-316-415	SNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPKLNDLCFTNVYAD SFVIRGDEVRQIAPGQT
S-346-445	RFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNKLPD DFTGCVIAWNSNNLDSKV
S-376-475	TFKCYGVSPKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNKLPDDFTGCVIAWNSNNLDSKGNNYNYLYRLF RKSNLKPFERDISTEIQQA
S-406-505	EVHQIAPGQTGKIADYNKLPDDFTGCVIAWNSNNLDSKGNNYNYLYRLFRKSNLKPFERDISTEIQAGSTP CNGVEGF NCYFP LQSYGQOPTNGVGY
S-436-535	WNSNNLDSKGNNYNYLYRLFRKSNLKPFERDISTEIQAGSTP CNGVEGFNCYFP LQSYGQOPTNGVGYQPYRVVVLSE LLHAPATVCGPKKSTNLVK
S-466-549	RDISTEIQAGSTP CNGVEGFNCYFP LQSYGQOPTNGVGYQPYRVVVLSELLHAPATVCGPKKSTNLVKNKCVNFNGL TGT
S-466-485	RDISTEIQAGSTPCNGVEG
S-476-495	GST CNGVEGFNCYFP LQSY
S-486-505	FNCYFPLQSYGQOPTNGVGY
S-476-486	GSTPCNGVEGF
S-476-487	GSTPCNGVEGFN
S-476-488	GSTPCNGVEGFNC
S-476-489	GSTPCNGVEGFNCY
S-476-490	GSTPCNGVEGFNCYF
S-476-491	GSTP CNGVEGFNCYFP
S-476-492	GSTP CNGVEGFNCYFP L
S-476-493	GSTP CNGVEGFNCYFP LQ
S-476-494	GSTP CNGVEGFNCYFP LQS
S-476-495	GSTP CNGVEGFNCYFP LQSY
S-477-495	STP CNGVEGFNCYFP LQSY
S-478-495	TP CNGVEGFNCYFP LQSY
S-479-495	P CNGVEGFNCYFP LQSY
S-480-495	CNGVEGFNCYFP LQSY
S-481-495	NGVEGFNCYFPLQSY
S-482-495	GVEGFNCYFPLQSY
S-483-495	VEGFNCYFPLQSY
S-484-495	EGFNCYFPLQSY
S-485-495	GFNCYFPLQSY
S-486-495	FNCYFPLQSY

Table S1. The summary of SARS-CoV-2 RBD and truncated peptide sequences.

The sequences recognized by 9E1 are colored in red.




Figure S2. Analysis of recombinant CRMA-fused truncated RBD proteins.

CRMA-fused truncated RBD proteins were evaluated by SDS-PAGE(A) and Western blot(B) with anti-His polyAb. CRMA-fused protein plasmids were transfromed into *E.coli* ER2566 and induced by IPTG for 8 hours. For a truncated protein, the left lane represented supernatant of induced *E.coli* after ultrasonication and the lane right represented inclusion body of induced *E.coli* after ultrasonication.

(C)Western blot analysis of 9E1 against CRMA-fused truncated RBD proteins.RBD-His expressed by 293F and CRMA-RBD expressed by *E.coli* were used as positive control. CRMA protein was used as negative control. 9E1 was diluted at 1 μ g/mL.




A**B****C**

Figure S3. Competition ELISA of 9E1 against truncated peptides.

Synthesized peptides(1μg) were precubated with 9E1-HRP and the reactivity of the mixture was evaluated with ELISA assay as described in Materials and Methods. The OD values marked by dotted lines were display in Figure 4.

Figure S5




Figure S4. ELISA reactivity of 9E1 against SARS-CoV RBD protein.

9E1 was serially diluted and evaluated for reactivity against SARS-CoV-2 and SARS-CoV RBD proteins.




Figure S5. Alignment of S protein of human coronaviruses.

The sequence recognized by 9E1 and corresponding sequences of other human coronaviruses S protein are marked in red color.

The sequence alignment was made by ESPript 3.0. Swiss-Prot entry numbers for the sequences are P0DTC2 (SARS-CoV-2), P59594 (SARS-CoV), P36334 (HCoV-OC43), Q0ZME7 (HCoV-HKU1), P15423 (HCoV-229E), Q6Q1S2 (HCoV-NL63) and W6A028 (MERS-CoV) .